Stavroula Baritaki, Sara Huerta-Yepez, Ma da Lourdas Cabrava-Haimandez, Marialuisa Sensi, Silvana Canevari, Massimo Libra, Manuel Penichet, Haiming Chen, James R Berenson, Benjamin Bonavida
Multiple myeloma (MM) is the second most common hematological and incurable malignancy of plasma cells with low proliferative activity in the bone marrow. MM patients initially respond to conventional therapy, however, many develop resistance and recurrences occur. We have identified RKIP as a novel gene product that is differentially overexpressed in MM cell lines and MM tissues compared to other studied tumors and normal bone marrow. This overexpression consisted, in large part, of a phosphorylated inactive form of RKIP at Ser153 (p-Ser153 RKIP)...
April 1, 2011: Forum on Immunopathological Diseases and Therapeutics